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A major impediment to successful bone marrow transplantation is the presence of 
immunocompetent T  lymphocytes in the donor graft which lead to the development 
of graft-vs.-host  disease  (GVHD).  All  too  frequently, the  final  outcome of severe 
GVHD episodes is  high morbidity and  death.  This paper represents the fifth in a 
series in which we search for reagents that have the requisite selectivity and consistency 
to  eliminate  GVHD.  In  mice GVHD  can  be overcome by treating  marrow  with 
complement-fixing  antibodies  directed  toward  Thy-l-expressing cells  (1,  2).  In  a 
previous report we showed that treatment of donor lymphohematopoietic grafts with 
monoclonal anti-Thy-l.2 plus complement (C)  (3) or monoclonal anti-Lyt-1 plus C 
(4)  was effective in eliminating GVHD  from allogeneic recipient mice. The use of 
homogeneous monoclonal antibody for this purpose is a  major advance because the 
reagent is uniquely defined, can be reproduced at will, and does not require adsorption 
protocols, which are difficult to standardize. Potential complications are presented by 
the use of complement which must  function in vivo or be supplied during in vitro 
pretreatment. Most notably, complement from nonhuman sources is frequently toxic 
for human bone marrow stem cells. We now report an alternative method for freeing 
donor bone marrow grafts of T  ceils by treating the marrow with a  hybrid protein 
formed by the covalent conjugation of monoclonal anti-Thy-l.2 to the toxin ricin. 
Ricin contains two disulfide linked subunits; the A chain inhibits ribosomal protein 
synthesis, and the B chain binds the protein to ubiquitous galactose-containing cell 
surface  receptors. The  native binding  specificity of ricin  can  be modified to  that 
dictated by covalently bound monoclonal anti-Thy-l.2 after competive blocking of 
the galactose-binding site on the B chain (5). The resulting protein hybrid is selectively 
toxic in vitro for Thy-l.2-bearing EL4 tumor cells. 
In the present study, we have shown that intact ricin protein coupled to monoclonal 
anti-Thy-1.2 can selectively block in vitro cell function. Additionally, pretreatment of 
donor cells with antibody-ricin and lactose before bone marrow transplantation across 
major histocompatibility barriers, protected irradiated recipients from lethal GVHD. 
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Materials  and  Methods 
Hybrid Synthesis and Purification. A description of synthesis of the anti-Thy-l.2-ricin molecule 
has been reported (5). Briefly, ricin is reacted with m-maleimidobenzoyl-N-hydroxysuecinimide 
ester to link maleimide residues to ricin. A standardized monoelonal IgG against Thy-l.2 (clone 
30-H12  derived by Ledbetter and Herzenberg [6]) was prepared for cross-linking by partial 
reduction  of disulfide bonds.  The  maleimide-linked ricin  was  mixed  with  the  sulfhydryl 
containing antibody, forming a nonreducible thioether linkage between the two species. 
Mice. C57BL/6 and BALB/c strains used in these experiments were bred and housed at the 
Minnesota Mouse Colony, University of Minnesota. Adult males (26-31  g)  were housed in 
conventional cages with filter lids. Bedding, food, and water were not sterilized. Transplanted 
animals were fed a fat-supplemented diet and antibiotic supplemented water ad libitum. 
Mitogenesis. Spleens were isolated in phosphate-buffered saline (PBS), passed through a nylon 
filter, and pelleted. The cells were resuspended in culture medium (Dulbeceos modified Eagle's 
medium plus sodium pyruvate, Hepes buffer, L-arginine, nonessential amino acids, folic acid 
and asparajgine, t-glutamine, 2-mercaptoethanol, and 2% pooled human sera) and plated so 
that 5 ×  10° cells were pipetted into 96-well flat-bottomed culture plates (Linbro Chemical Co., 
Hamden, CT) in 0.2-ml vol. To activate B lymphocytes, 25 #g/well lipopolysaceharide (LPS) 
from Escherichia coli 0111  (Difco Laboratories, Detroit, MI) was added. T  lymphocytes were 
stimulated by the addition of 0.1  #g/well phytohemagglutinin (PHA)  (Difco Laboratories). 
Cultures were pulsed with 1 #Ci tritiated thymidine (specific activity 15 Ci/mmol) 24 h before 
harvest on  day  3.  Cultures  were collected by precipitation onto  glass fiber filters with  an 
automated harvester, and thymidine incorporation was measured in a Beckman LS300 scintil- 
lation counter (Beckman Instruments Inc., Fullerton, CA) by standard counting methods. 
Data were presented as percent control response and calculated as: 
(CPM mitogen-stimulated lymphocytes +  anti-Thy-1.2-ricin) 
-  (CPM lymphocytes +  anti-Thy-l.2-ricin) 
percent control =  ×  100. 
(CPM mitogen-stimulated lymphocytes untreated) 
-  (CPM lymphocytes untreated) 
Total-body Irradiation. Irradiation was delivered from a 220 kV x-ray source (General Electric 
Maximar-20, General Electric Co., Wilmington, MA) at  15 mA through 0.25-mm copper and 
1.0-ram aluminum filters. Animals were positioned in lucite radiation chambers and exposed at 
a dose-rate of 50 rad/min to a total of 900 rad. 
Transplantation. C57BL/6  mice were transplanted with BALB/c bone marrow plus spleen 
cells (BMS) as described in a  previous report (3).  25 X  106 donor splenoeytes were combined 
with an equal number of bone marrow cells and injected intravenously in 0.5 ml media. 
Pretreatment of Donor Cells. Donor BMS cells were treated with monoclonal anti-Thy-1.2-ricin 
before injection into irradiated recipients. Based on in vitro studies, cells were adjusted to 10T/ 
ml in RPMI 1640, 200 mM lactose (Difco Laboratories) and preincubated at 37°C for 3 h with 
0.5 #g/ml hybrid. Cells were then washed three times in media containing 100 mM lactose and 
resuspended for injection. Another group of recipients were given donor cells pretreated with 
0.5  #g/ml  antibody alone.  For mitogen  assays,  anti-Thy-l.2-ricin and  lactose were  added 
directly to culture wells and remained throughout the assays. 
Assay for Chimerism. Survival of bone marrow allografts was measured by the presence of 
donor-type mononuclear cells in the peripheral blood. Donor cells were detected using H-2- 
specific antisera in an in vitro complement-dependent microeytotoxicity assay, which has been 
previously described (7). 
Assessment of GVHD. Following injection of treated or untreated BMS, animals were observed 
for the development of secondary disease. Autopsies revealed conspicuous pathological changes 
associated with GVHD including emaciation, hepatic lesions, lymphoid atrophy, colitis, and 
diarrhea. Histologic examinations were performed on select animals. 
Results 
Inhibition of PHA Mitogenesis with Anti-Thy-l.2-Ricin.  To determine whether antibody- 
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cultured in the presence of a  stimulatory dose of PHA.  (Fig.  1). Proliferative activity 
was measured by tritiated  thymidine incorporation after 3 d. Activity was increased 
48-fold (184,427 cpm) compared with cultures that were incubated in the absence of 
PHA  (3,823  cpm)  (see legend to Fig.  1).  When 0.2 or 0.5/~g anti-Thy-l.2-ricin  was 
added to mitogen-stimulated cultures in the presence of lactose, which competitively 
blocks  galactose  receptors  on  the  hybrid  molecule,  PHA  responses  were  reduced 
89  and  94%,  respectively,  compared  with  the  level  of activity  in  control  cultures 
(BALB/c splenocytes in the presence of mitogen).  1 ~g/ml hybrid reduced activity 
even further. In contrast, when BALB/c splenocytes were cultured in the presence of 
the B lymphocyte-dependent mitogen LPS, 0.2/zg/ml and 0.5 #g/ml hybrid inhibited 
mitogenesis only 29 and 30% compared with control cultures.  1 #g/ml treatment had 
a much greater toxic effect. No protection was measured against the toxicity of hybrid 
when  cells  were  incubated  in  the  presence  of mitogen,  but  without  lactose  in  the 
culture  system.  Those concentrations  of hybrid  plus  lactose which  inhibited  PHA- 
induced responses of BALB/c splenocytes had no effect on AKR splenocytes, which 
do not express Thy-l.2 antigen on their surfaces (not shown). 
Protection of Allogeneic Irradiated Recipients from Lethal GVHD by Pretreatment of Donor 
Cells with Anti-Thy-l.2-Ricin.  To determine whether GVHD-causing T  cells could be 
eliminated from donor grafts with the anti-Thy-1.2-ricin hybrid before bone marrow 
transplantation,  C57BL/6 mice were conditioned with 900 rad total-body irradiation 
(TBI).  Irradiated  recipients  (n  =  12)  given  BALB/c  BMS  (Allo-BMS)  developed 
GVHD  and  showed  a  high  (>90%)  mortality  rate  (Fig.  2).  These  animals  had 
engrafted before their death  (not shown).  Survival was significantly improved (91%) 
in recipients  (n =  1 I) given donor BMS treated with antibody-ricin conjugate in the 
presence of lactose before injection.  Surviving mice appeared healthy and showed no 
evidence of GVHD or subclinical GVHD on autopsy. Some degree of protection was 
conferred by treatment of donor BMS grafts with antibody alone (n --  18); however, 
as previously reported  (3), this protection was only transient  as recipients eventually 
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FIo.  1.  BALB/c splenocytes were cultured in vitro in the presence of mitogens PHA (F'I) or LPS 
(B). Varying amounts of aThy-l.2-ricin  hybrid were added at the initiation of cultures, both with 
and without lactose. After 3 d cells were pulsed with tritiated thymidine, harvested, and counted by 
standard  methods. Untreated  cells responded vigorously to mitogens as follows: BALB/c cells + 
PHA --  184,427 cpm; BALB/c cells +  LPS -- 32,918 cpm; BALB/c cells alone --  3,823 cpm. 
Standard  deviations of mean triplicate samples did not exceed 17%. Data are shown as percent 
control response in which the response of treated (aThy-l.2-ricin) cells is compared with untreated 
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FIG. 2.  A group of C57BL/6 mice were conditioned with 900 rad TBI and given AIIo-BMS. Two 
other groups of recipients were given donor ceils pretreated with 0.5 ~g/ml anti-Thy-1.2-ricin plus 
lactose (Allo-BMS +  aThy-l.2-ricin) or 0.5 ~g/ml monoclonal anti-Thy-l.2 antibody alone (Allo- 
BMS  +  aThy-l.2).  Calculation  of survival  results  and  statistical  analysis  have  been  reported 
elsewhere (3). x-square analysis, which compared values over the entire length of the actuarial curve, 
showed that group Allo-BMS +  ~Thy-h2-ricin differed significantly from groups Allo-BMS and 
AIIo-BMS +  aThy-l.2  (P <  0.00l).  Also, group Allo-BMS +  aThy-l.2 differed significantly from 
group AIIo-BMS (P <  0.003).  Group Allo-BMS contained 12 members; Allo-BMS +  aThy-l.2,  18 
members; and Allo-BMS +  otThy- 1.2-ricin, 11 members. 
developed GVHD and survival was <28%  by day 70. Control animals given grafts 
pretreated with 200 mM lactose alone or anti-Thy- 1.1-ricin plus 200 mM lactose were 
not  protected from GVHD  (not  shown).  As  further control, a  group of irradiated 
C57BL/6 recipients were given syngeneic BMS cells. All of these mice remained alive, 
suggesting that deaths were not attributable to the toxicity of the radiation protocol 
(not  shown).  The  data  presented  in  Fig.  2  are  representative  of an  experiment 
performed three times. To determine whether anti-Thy-1.2-ricin pretreatment resulted 
in engraftment, recipients from Fig.  2 were serotyped. A  high percentage of donor- 
type (H-2  a)  cells  (a mean of 80%)  were in  the peripheral blood of these C57BL/6 
mice 50-60 d after transplant. 
Discussion 
We have used a  previously described model  (3)  in which  the injection of donor 
bone marrow cells and splenocytes induces severe GVHD across major H-2 barriers. 
With death as a  measured endpoint, elimination of immunocompetent T  cells from 
donor grafts with monoclonal antibody plus complement protects irradiated recipi- 
ents.  Unfortunately, difficulties with complement sources and standardization  pre- 
clude large-scale clinical use of this approach. In these studies we have circumvented 
the need for complement by synthesizing a cell type specific toxin made by linking 
ricin  to anti-Thy-l.2 monoclonal antibody and  then  blocking the  ricin  galactose- 
binding site with exogenous lactose. This conjugate was effective in inhibiting protein 
synthesis of Thy-l.2-bearing EL4 tumor cells as reported (5).  Moreover, the hybrid 
effectively eliminated the proliferative response of splenic T  lymphocytes induced by 
T  cell specific mitogen stimulation  (Fig.  1). Although the conjugate did inhibit a  B 
cell mitogen-induced response to some degree (=29%), this could be attributed to the 
fact that antibody-ricin was left in the culture system during the entire duration of 
the  assay  and/or  that  a  T  cell  mitogenic contamination  was  present  in  the  LPS VALLERA ET  AL.  BRIEF  DEFINITIVE  REPORT  953 
preparation. Nonspecific stem cell toxicity was not encountered when donor cells were 
treated  with  antibody-ricin  before  transplant  because  recipients  engrafted 
and displayed a high percentage of donor cells (>80%) in their peripheral blood. 
Interestingly,  in  our  transplant  experiments  it  is  apparently  not  necessary  to 
eliminate all splenic T  cells for successful therapy, as we have observed (8) that TBI- 
conditioned C57BL/6  mice  given BALB/c marrow  containing  1% T  lymphocytes 
results in 60% survivors at  100 d post-transplant. Furthermore, Korngold and Sprent 
(9)  showed in a  system in which lethal GVHD could be induced across minor H-2 
barriers, that  by reducing the number of immunocompetent T  cells present  in the 
donor graft to 3 ×  104, 20% survivors remained at 80 d post-transplant. Thus, during 
pretreatment, it may only be necessary to reduce the number of surviving T  cells to 
108 or  104 to achieve successful therapy in the mouse.  Previous studies  (10)  on the 
ability of an anti-Thy-l.2 ricin conjugate to kill Thy-l.2-positive cells show that this 
range is achievable without severely depleting Thy-1.2 negative cells. 
The hybrid used in these studies contains the ricin B chain to facilitate the entry of 
ricin A  chain  into the cytosol compartment.  This is  a  necessary condition, as  the 
affinity of the antibody used in the hybrid is only 10  n M -x measured with EL-4 cells 
at 25°C using l~I-anti-Thy-l.2 (unpublished data). We have shown that the presence 
of the ricin B chain enhances the entry rate of ricin A chain into the cytosol and leach 
to  more  rapid  killing  and  a  lower  fraction  of survivors  (10).  Entry  rate  is  also 
proportional to the number of occupied receptors. Consequently, hybrids made with 
relatively low affinity antibody, as in the present case, require the ricin B chain to 
achieve the necessary entry rate and low fraction of  cell survivors. These considerations 
indicate that future anti-T cell hybrids of much greater selectivity can be constructed. 
Others  have used  preparations  of monoclonal antibodies  conjugated  directly to 
ricin A chain (11), circumventing the need for addition of exogenous lactose. Such a 
system would be valuable in certain cases where direct therapy with the hybrid was 
requisite, but at the present time a superiority of an A chain-antibody conjugate over 
an  intact  ricin has not  been established.  A  direct comparison of Thy-1.1  antibody 
linked to intact ricin and antibody-linked A  chain in vitro shows that both hybrids 
are effective, but that the intact ricin hybrid can have a faster rate of Cell killing (10). 
In this report, we have shown that monoclonal antibodies conjugated to intact ricin 
can be used to pretreat donor cells to specifically eliminate GVHD-causing cells. Such 
conjugates  may serve as  unique  and  powerful  tools  to  control  GVHD  in  human 
transplantation  because of the  simplicity of the  treatment  protocol.  Furthermore, 
because the cells are incubated with hybrid and washed before injection, the risk of 
toxic effects against host tissue is minimized. Together, these studies suggest that the 
conjugation  of ricin  to  antihuman  T  cell  antibodies  may provide useful  tools  for 
treatment of donor bone marrow in vitro before transplantation,  permitting trans- 
plantation across major histocompatibility barriers. 
Summary 
A  new method has been devised to eliminate T  cells from murine bone marrow 
grafts across major histocompatibility barriers and thus prevent graft-vs.-host disease 
(GVHD). The method utilizes a monoclonal antibody directed at the Thy-1.2 antigen 
but is complement independent. To make anti-Thy-l.2 toxic, the antibody is cova- 
lently linked to the toxin ricin. Ricin ordinarily binds, enters, and kills cells through 954  VALLERA ET AL.  BRIEF DEFINITIVE REPORT 
receptors containing galactose. The hybrid protein, anti-Thy-l.2-ricin, can enter and 
kill cells via the Thy-l.2 receptor. In the presence of lactose the usual entry route for 
riein is largely blocked and the hybrid is shown to be a  highly selective reagent that 
is T  cell specific in its inhibition of mitogen-stimulated splenocytes. 
We have used a  model of severe and fatal GVHD where BALB/c splenocytes and 
bone  marrow  cells  are  given  to irradiated  C57BL/6  recipients.  Over 90%  of these 
mice die by day 70, exhibiting signs of GVHD. When donor cells are pretreated with 
0.5/~g/ml of anti-Thy-l.2-ricin plus 200 mM lactose before injection,  10 of 11 animals 
survive through day 70 without signs of GVHD. These studies demonstrate that ricin 
linked to monoelonal antibodies may have utility related to the prevention of GVHD 
in human bone marrow transplantation. 
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